HT
TVTX icon

Headlands Technologies’s Travere Therapeutics TVTX Stock Holding History

Headlands Technologies’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,936
Closed -$73.1K – 1243
2025
Q2 		$73.1K Buy
+4,936
New +$81.8K 0.01% 692
2025
Q1 		– Sell
-4,048
Closed -$70.5K – 1529
2024
Q4 		$70.5K Sell
4,048
-9,637
-70% -$170K 0.01% 740
2024
Q3 		$191K Buy
+13,685
New +$143K 0.02% 536
2024
Q2 		– Sell
-302
Closed -$2.33K – 1615
2024
Q1 		$2.33K Sell
302
-2,309
-88% -$19.5K ﹤0.01% 1155
2023
Q4 		$23.5K Buy
+2,611
New +$19K 0.01% 644

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Headlands Technologies's TVTX Position: Q3 2025 in Review

Headlands Technologies sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 4,936 shares — an estimated $73.1K sold.

Headlands Technologies first reported a position in TVTX in Q4 2023 and held it in 5 quarters. The position peaked at $191K in Q3 2024. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Headlands Technologies reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Headlands Technologies sold 4,936 Travere Therapeutics shares in Q3 2025, an estimated $73.1K.
  • Headlands Technologies first reported a position in Travere Therapeutics in Q4 2023 and held it in 5 quarters.
  • Headlands Technologies's Travere Therapeutics position peaked at $191K in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Headlands Technologies's 13F filing for Q3 2025, filed 12 Nov 2025.